First Subject Dosed in Lipigon s Phase I Clinical Study with Antisense Oligonucleotide Candidate Derived from Secarna Pharmaceutical s LNAplus(TM) Technology Platform
tennesseedaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tennesseedaily.com Daily Mail and Mail on Sunday newspapers.
Relief and AdVita Announce Initiation of Phase 2 Trial with Inhaled RLF-100 for the Prevention of CO
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
Share:
Relief or the
Company ), commented today on certain statements made by NeuroRx, Inc., its collaboration partner for the development of RLF-100
TM (aviptadil) pursuant to that certain binding collaboration agreement, dated September 18, 2020 (the Collaboration Agreement ), in Amendment No. 1 to the Form S-4 of Big Rock Partners Acquisition Corp. s ( BPRA ) that was filed on Friday, April 16, 2021 (the Amendment ). The Amendment was filed by BRPA with respect to the proposed merger between NeuroRx and BRPA.
NeuroRx has elected to make statements in the Amendment with respect to pending disputes between Relief and NeuroRx under the terms of the Collaboration Agreement. As a result, Relief has concluded that it must inform the public about the nature of the pending disputes and its views regarding the positions regarding these issues taken by its collaboration partner. The issues currently in dispute include the following: